Trial Profile
Retrospective study of Gefitinib, Erlotinib, and Afatinib in patients with Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Dec 2018 New trial record